CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo

Cancer Research

Volumn 59, Issue 22, 1999, Pages 5751-5757

  Vig Hjarnaa, Pernille Julia ^a   Jonsson, Elin ^b   Latini, Scilla ^a   Dhar, Sumeer ^b   Larsson, Rolf ^b   Bramm, Erik ^a   Skov, Torsten ^a   Binderup, Lise ^a  

^a LEO PHARMA A S   (Denmark)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DAUNORUBICIN; ETOPOSIDE; GUANIDINE DERIVATIVE; METHOTREXATE; N (6 CHLOROPHENOXYHEXYL) N' CYANO N'' (4 PYRIDYL)GUANIDINE; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL STRAIN MCF 7; FEMALE; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, SMALL CELL; CYANIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GUANIDINES; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; SARCOMA, YOSHIDA; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033571407     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Schou, C., Ottosen, E. R., Björkling, F., Latini, S., Hjarnaa, P. V., Bramm, E., and Binderup, L. Novel cyanoguanidines with potent oral antitumour activity. Bioorg. & Med. Chem. Lett., 7: 3095-3100, 1997.
2. Petersen, H. J., Kærgaard Nielsen, C., and Arrigoni-Martelli, E. Synthesis and hypotensive activity of N-alkyl-N″-cyano-N′-pyridylguanidines. J. Med. Chem., 21: 773-781, 1978.
3. Dhar, S., Nygren, F., Csoka, K., Botling, J., Nilsson, K., and Larsson, R. Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br. J. Cancer, 74: 888-896, 1996.
4. Sundström, C., and Nilsson, K. Establishment and characterisation of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer, 17: 565-577, 1976.
5. Botling, J., Liminga, G., Larsson, R., Nygren, P., and Nilsson, K. Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170kDa P-glycoprotein. Int. J. Cancer, 58: 269-274, 1994.
6. Dalton, W. S., Durie, B. G. Alberts, D. S., Gerlach, J. H., and Cress, A. E. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res., 46: 5125-5130, 1986.
7. Bellamy, W. T, Dalton, W. S, Gleason, M. C., Grogan, T. M. and Trent, J. M. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res., 51: 995-1002, 1991.
8. Mulcahy, R. T., Bailey, H. H., and Gipp, J. J. Up-regulation of γ-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother. Pharmacol., 34: 67-71, 1994.
9. Cole, S. P., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistance human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
10. Mirski, S. E., Gerlach, J. H., and Cole, S. P. Multidrug resistance in a human small cell lung cancer cell line selected in Adriamycin. Cancer Res., 47: 2594-2598, 1987.
11. Danks, M. K., Schmidt, C. A, Cirtain, M. C., Suttle, D. P., and Beck, W. T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry, 27: 8861-8869, 1988.
12. Danks, M. K., Yalowich, J. C., and Beck, W. T. Atypical multidrug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res., 47: 1297-1301, 1987.
13. 2+ concentration. Biosci. Rep., 10: 231-237, 1990.
14. Larsson, R., Kristensen, J., Sandberg, C., and Nygren, P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer, 50: 177-185, 1992.
15. Brünner, N., Bronzert, D., Vindeloev, L. L., Spang-Thomsen, M., and Lippmann, M. E. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res., 49: 1515-1520, 1989.
16. Tomayko, M. M., and Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol., 24: 148-154, 1989.
17. Aabo, K., Vindeloev, L. L., and Spang-Thomsen, M. Clonal dominance between subpopulations of mixed small cell lung cancer xenografts implanted ectopically in nude mice. Eur. J. Cancer, 31A: 222-229, 1995.
18. Aabo, K., Roed, H., Vindeloev, L. L., and Spang-Thomsen, M. A dominated and resistant subpopulation causes regrowth after response to 1,3-bis(2-chloroethyl)-1-nitrosurea treatment of a heterogeneous small cell lung cancer xenograft in nude mice. Cancer Res., 54: 3295-3299, 1994.
19. Marusic, M., Allegretti, N., and Culo, F. The timing of cyclophosphamide therapy in tumor-bearing rats affects the resistance to tumor challenge in survivors. Experientia, 34: 1355-1356, 1978.
20. Fujita, H., Sakurai, T., and Toyoshima, S. New antitumor amino acid derivative, A-748, evaluated in rat ascites hepatomas. Cancer Treat. Rep., 63: 223-224, 1979.
21. Minne, H. W., Raue, F., Bellwinkel, S., and Ziegler, R. The hypercalcaemic syndrome in rats bearing the Walker carcinosarcoma 256. Acta Endocrinol., 78: 613-624, 1975.
22. Boyd, M. R., and Paull, K. D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res., 34: 91-109, 1995.
23. Smets, L. A., Bout, B., and Wisse, J. Cytotoxic and antitumour effects of the norepinephrine analogue meta-iodo-benzylguanidine (MIBG). Cancer Chemother. Pharmacol., 21: 9-13, 1988.
24. Loesberg, C., Van Rooij, H., Romijn, J. C., and Smets, L. A. Mitochondrial effects of the guanidino group-containing cytostatic drugs, m-iodobenzylguanidine and methylglyoxal bis (guanylhydrazone). Biochem. Pharmacol., 42: 793-798, 1991.
25. Thompson, A. M., Steel, C. M., Chetty, U., Hawkins, R. A., Miller, W. R., Carter, D. C., Forrest, A. P., and Evans, H. J. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br. J. Cancer, 61: 74-78, 1990.
26. Helin, K., Holm, K., Niebuhr, A., Eiberg, H., Tommerup, N., Hougaard, S., Poulsen, H. S., Spang-Thomsen, M., and Nørgaard, P. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc. Natl. Acad. Sci. USA, 94: 6933-6938, 1997.
27. Fridborg, H., Nygren, P., Dhar, S., Csoka, K., Kristensen, J., and Larsson, R. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumour cell lines and patient biopsy cells. J. Exp. Ther. Oncol., 1: 286-295, 1996.
28. Jonsson, E., Fridborg, H., Csoka, K., Dhar, S., Sundström. C., Nygren, P., and Larsson, R. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br. J. Cancer, 76: 211-219, 1997.
29. Dhar, S., Nygren, P., Liminga, G., Sundström, C., de la Torre, M., Nilsson, K., and Larsson, R. Relationship between cytotoxic drug response patterns and activity of drug efflux transporters mediating multidrug resistance. Eur. J. Pharmacol., 346: 315-322, 1998.
30. Plowman, J., Dykes, D. J., Hollingshead, M., Simpson-Herren, L., and Alley, M. C. Human Tumor Xenograft Models in NCI Drug Development. In: B. A. Teicher (ed.), Anticancer Drug Development Guide, pp. 101-125. New Jersey: Humana Press, 1997.